Single-centre Descriptive Study of Taste in Frontotemporal Lobar Degeneration Through the Analysis of Taste Evoked Potentials

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire Dijon

About this trial

The FRONTAL-PEG study focuses on taste perception in frontotemporal lobar degeneration (FTLD). This neurodegenerative disease, characterised by progressive loss of nerve cells, is the second leading cause of dementia after Alzheimer's disease.

Patients with FTLD often experience olfactory disorders (= sense of smell) and eating disorders: increased appetite, increased food intake and excessive consumption of sugary foods and snacking. This often leads to excessive weight gain. These eating disorders are still poorly understood at present.

In this context, we hypothesise that an alteration in the gustatory pathway - i.e. the way in which the brain perceives taste - could contribute to the eating disorders frequently observed in frontotemporal dementia (FTD), particularly in the marked attraction to sweet foods. We therefore wish to objectively evaluate the taste response to a sweet solution (sucrose) in patients with FTLD, using taste evoked potentials (TEPs). Taste evoked potentials are a reliable and reproducible technique for assessing brain activity in response to taste stimulation. One of their advantages is that they are non-invasive.

This study will document, for the first time in this disease, the characteristics of cortical (brain) processing of taste information.

The FRONTAL-PEG study is an interventional, regional, single-centre study conducted at the Dijon University Hospital, in collaboration with the CMRR (Memory, Resources and Research Centre) and the CSGA (Centre for Taste and Food Sciences).

All investigations are carried out at the CSGA (building adjacent to the Dijon University Hospital), with the exception of blood tests, which are carried out at the Dijon University Hospital.

The total duration of participation in the study is one morning. No follow-up is planned at the end of the study.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Person who has given their free and informed consent

Person of legal age

Fasting > 2 hours before PEG measurement

Body Mass Index (BMI) < 30 kg/m² (according to medical record data)

Disqualifiers

Persons not affiliated with or not covered by a social security scheme

Persons subject to legal protection measures (guardianship, trusteeship)

Persons subject to judicial protection measures

Pregnant women, women in labour or breastfeeding women

Trial design

Design model

Single group

Treatments tested in this trial

  • Blood test

    Biological/Vaccine

    Metabolic measurements and measurements of hormones related to food intake

  • Interrogation of the subject

    Other intervention

    Collection of socio-demographic data, medical and family history, medication

  • Cognitive assessment

    Other intervention

    MMSE and MoCA cognitive tests

  • Nutritional assessment

    Other intervention

    Anthropometric data (weight, height, BMI, waist circumference, hip circumference, android/gynoid ratio, triceps skinfold thickness, brachial circumference), bioelectrical impedance analysis (body fat percentage, lean body mass, body water percentage and bone mass in kg)

  • Taste tests

    Other intervention

    Recording of PEGs in response to a sucrose solution (prepared beforehand)

  • Sucrose taste detection test

    Other intervention

    Triangular test

Treatment groups

20 Participants
are divided into 1 treatment group
Group A: Patients with frontotemporal lobar degenerationExperimental treatment 6 interventions

Trial outcomes

Primary outcomes

1

Average latency of taste evoked potentials

Time frame
After a fasting period of at least two hours

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.